Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for Alzheimer’s Disease

Hoboken, NJ — July 26, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.” Neuroprotective, anti-amnesic, anti-depressive…